Case report: A kidney transplant patient with mild COVID‐19

Arpalı, Emre; Akyollu, Basak; Yelken, Berna; Tekin, Süda; Türkmen, Aydın; Koçak, Burak

doi:10.1111/tid.13296

Cited by 52 publications

(57 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A review of available renal transplant cases can be found in Table 1. 4,7,[10][11][12][13][14][15] Overall, our patient did well without experimental antiviral or anti-inflammatory therapies and experienced no serious complications, including need for hospitalization or supplemental oxygenation. In fact, the patient appeared well enough that the ED did not order labs beyond respiratory virus and SARS-CoV-2 testing.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

COVID‐19 in an HIV‐positive kidney transplant recipient

Kumar

Tanna

Shetty

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 66%

“…There have been reported cases of COVID-19 in HIV-infected patients and cases of COVID-19 in transplant recipients. [4][5][6][7][8][9][10][11][12][13][14][15] However, this case is the first detailed report of an HIV-positive kidney transplant recipient who developed and recovered from COVID-19.…”

Section: Discussionmentioning

confidence: 84%

COVID‐19 in an HIV‐positive kidney transplant recipient

Kumar

Tanna

Shetty

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Among the smaller case series and individual case reports, notable findings included SOT recipients with COVID‐19 who were early in their posttransplant course and had favorable outcomes 18‐20 . Authors from Italy describe their experience with 6 liver transplant patients, among whom 3 were less than 2 years posttransplant and had mild disease, whereas the 3 who were > 10 years from transplant died 20 .…”

Section: Literature Reviewmentioning

confidence: 99%

Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States

Fung

Chiu

DeVoe

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic caused by SARS coronavirus 2 (SARS‐CoV‐2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID‐19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID‐19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID‐19 in SOT recipients to consolidate the current knowledge on COVID‐19 in the SOT population for the transplant community.

show abstract

“…One unresolved issue about COVID-19 is the influence of immunosuppressive treatments (ISTs) on disease occurrence and course. The results published so far are rather contradictory, with authors reporting either mild [ 6 , 7 , 8 , 9 , 10 , 11 , 12 ] or severe disease course with high mortality [ 13 , 14 , 15 , 16 , 17 , 18 ]. These differences could be due to the different approaches adopted for therapy management (continuation or interruption of ISTs).…”

Section: Introductionmentioning

confidence: 99%

Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy

et al. 2020

View full text Add to dashboard Cite

The role of immunosuppression in SARS-CoV-2-related disease (COVID-19) is a matter of debate. We here describe the course and the outcome of COVID-19 in a cohort of patients undergoing treatment with calcineurin inhibitors. In this monocentric cohort study, data were collected from the COVID-19 outbreak in Italy up to 28 April 2020. Patients were followed at our hospital for solid organ transplantation or systemic rheumatic disorders (RMDs) and were on calcineurin inhibitor (CNI)-based therapy. Selected patients were referred from the North of Italy. The aim of our study was to evaluate the clinical course of COVID-19 in this setting. We evaluated 385 consecutive patients (220 males, 57%; median age 61 years, IQR 48–69); 331 (86%) received solid organ transplantation and 54 (14%) had a RMD. CNIs were the only immunosuppressant administered in 47 patients (12%). We identified 14 (4%) COVID-19 patients, all transplanted, mainly presenting with fever (86%) and diarrhea (71%). Twelve patients were hospitalized and two of them died, both with severe comorbidities. No patients developed acute respiratory distress syndrome or infectious complications. The surviving 10 patients are now fully recovered. The clinical course of COVID-19 patients on CNIs is generally mild, and the risk of superinfection seems low.

show abstract

Case report: A kidney transplant patient with mild COVID‐19

Cited by 52 publications

References 21 publications

COVID‐19 in an HIV‐positive kidney transplant recipient

COVID‐19 in an HIV‐positive kidney transplant recipient

Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States

Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy

Contact Info

Product

Resources

About